The Uptake of the Pharmacy-dispensed Naloxone Kit Program in Ontario: A Population-based Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Oct 19

PMID 31626648

Citations 18

Authors

Beatrice Choremis

Tonya Campbell

Mina Tadrous

Diana Martins

Tony Antoniou

Tara Gomes

Affiliations

Soon will be listed here.

Abstract

Background: Naloxone is a life-saving antidote for opioid overdoses. In June 2016, the Ontario government implemented the Ontario Naloxone Program for Pharmacies (ONPP) to enhance access to naloxone.

Objective: We examined the initial uptake of naloxone through the ONPP and characteristics of the individuals receiving and pharmacies dispensing naloxone kits.

Methods: We conducted a population-based study of all Ontario residents who received a naloxone kit between July 1, 2016 and March 31, 2018. This involved 1) a cross-sectional analysis of monthly rates of kits dispensed; and 2) a descriptive analysis of all individuals and pharmacies who accessed and dispensed naloxone, respectively. We stratified individuals according to their opioid exposure as: prescription opioid agonist therapy (OAT) recipients, prescription opioid recipients, those with past opioid exposure and those with no/unknown opioid exposure. We calculated a Lorenz curve comparing the cumulative percent of naloxone-dispensing pharmacies and cumulative percent of naloxone kits dispensed and the corresponding Gini coefficient.

Results: Naloxone dispensing through the ONPP increased considerably from 1.9 to 54.3 kits per 100,000 residents over the study period. In this time, 2,729 community pharmacies dispensed 91,069 kits to 67,910 unique individuals. Uptake was highest among prescription OAT recipients (40.7% of OAT recipients dispensed at least one kit), compared with 1.6% of prescription opioid recipients, 1.0% of those with past opioid exposure and 0.3% with no/unknown opioid exposure. Naloxone dispensing was highly clustered among pharmacies (Gini = 0.78), with 55.6% of Ontario pharmacies dispensing naloxone, and one-third (33.7%) of kits dispensed by the top 1.0% of naloxone-dispensing pharmacies.

Conclusion: The ONPP launch led to a rapid increase in the number of naloxone kits dispensed in Ontario. Although the program successfully engaged people prescribed OAT, efforts to increase uptake among others at risk of opioid overdose appear warranted. Opportunities for expanding pharmacy participation should be identified and pursued.

Citing Articles

Adapting the Opening Minds Stigma Scale for Healthcare Providers to Measure Opioid-Related Stigma.

Cid A, Patten A, Beazely M, Grindrod K Pharmacy (Basel). 2024; 12(4).

PMID: 39051389 PMC: 11270195. DOI: 10.3390/pharmacy12040105.

Retrospective study investigating naloxone prescribing and cost in US Medicaid and Medicare patients.

Manko C, Ahmed M, Harrison L, Kodavatiganti S, Lugo N, Konadu J BMJ Open. 2024; 14(5):e078592.

PMID: 38692729 PMC: 11086430. DOI: 10.1136/bmjopen-2023-078592.

Understanding the barriers and facilitators to implementing and sustaining Mobile Overdose Response Services from the perspective of Canadian key interest groups: a qualitative study.

Seo B, Rider N, Rioux W, Teare A, Jones S, Taplay P Harm Reduct J. 2024; 21(1):28.

PMID: 38308262 PMC: 10837862. DOI: 10.1186/s12954-024-00946-7.

"It can save your life, that's all I know," barriers and facilitators for engagement in take-home naloxone for people receiving opioid substitution treatment in regional Australia: An explorative study.

Natale I, Harvey C, Wood P, Anderson K Qual Res Med Healthc. 2023; 7(2):10868.

PMID: 37692452 PMC: 10483482. DOI: 10.4081/qrmh.2023.10868.

Feasibility and acceptability of inserts promoting virtual overdose monitoring services (VOMS) in naloxone kits: a qualitative study.

Safi F, Rioux W, Rider N, Fornssler B, Jones S, Ghosh S Harm Reduct J. 2023; 20(1):64.

PMID: 37158926 PMC: 10165834. DOI: 10.1186/s12954-023-00792-z.

References

Cressman A, Mazereeuw G, Guan Q, Jia W, Gomes T, Juurlink D . Availability of naloxone in Canadian pharmacies:a population-based survey. CMAJ Open. 2017; 5(4):E779-E784. PMC: 5741422. DOI: 10.9778/cmajo.20170123. View

Bagley S, Peterson J, Cheng D, Jose C, Quinn E, OConnor P . Overdose Education and Naloxone Rescue Kits for Family Members of Individuals Who Use Opioids: Characteristics, Motivations, and Naloxone Use. Subst Abus. 2015; 36(2):149-54. PMC: 4809347. DOI: 10.1080/08897077.2014.989352. View

Levy A, OBrien B, Sellors C, Grootendorst P, Willison D . Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003; 10(2):67-71. View

Martins D, Khuu W, Tadrous M, Juurlink D, Mamdani M, Paterson J . Impact of delisting high-strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada. Pharmacoepidemiol Drug Saf. 2019; 28(5):726-733. PMC: 6518867. DOI: 10.1002/pds.4764. View

Freeman L, Bourque S, Etches N, Goodison K, OGorman C, Rittenbach K . Alberta's provincial take-home naloxone program: A multi-sectoral and multi-jurisdictional response to overdose. Can J Public Health. 2017; 108(4):e398-e402. PMC: 6972089. DOI: 10.17269/cjph.108.5989. View

Madadi P, Hildebrandt D, Lauwers A, Koren G . Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada. PLoS One. 2013; 8(4):e60600. PMC: 3618438. DOI: 10.1371/journal.pone.0060600. View

Wong L, Burden A, Liu Y, Tadrous M, Pojskic N, Dolovich L . Initial uptake of the Ontario Pharmacy Smoking Cessation Program: Descriptive analysis over 2 years. Can Pharm J (Ott). 2016; 148(1):29-40. PMC: 4294811. DOI: 10.1177/1715163514562038. View

Mamdani M, Sykora K, Li P, Normand S, Streiner D, Austin P . Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ. 2005; 330(7497):960-2. PMC: 556348. DOI: 10.1136/bmj.330.7497.960. View

McDonald R, Strang J . Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016; 111(7):1177-87. PMC: 5071734. DOI: 10.1111/add.13326. View

10.

Coffin P, Sullivan S . Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013; 158(1):1-9. DOI: 10.7326/0003-4819-158-1-201301010-00003. View

11.

Banjo O, Tzemis D, Al-Qutub D, Amlani A, Kesselring S, Buxton J . A quantitative and qualitative evaluation of the British Columbia Take Home Naloxone program. CMAJ Open. 2014; 2(3):E153-61. PMC: 4183165. DOI: 10.9778/cmajo.20140008. View

12.

Kerr T, Mitra S, Kennedy M, McNeil R . Supervised injection facilities in Canada: past, present, and future. Harm Reduct J. 2017; 14(1):28. PMC: 5437687. DOI: 10.1186/s12954-017-0154-1. View

13.

Leece P, Gassanov M, Hopkins S, Marshall C, Millson P, Shahin R . Process evaluation of the Prevent Overdose in Toronto (POINT) program. Can J Public Health. 2016; 107(3):e224-e230. PMC: 6972389. DOI: 10.17269/cjph.107.5480. View

14.

Rosenberg-Yunger Z, Ellen M, Mickleborough T . The North American Opioid Experience and the Role of Community Pharmacy. J Public Health Manag Pract. 2018; 24(4):301-305. DOI: 10.1097/PHH.0000000000000807. View

15.

Gomes T, Mamdani M, Dhalla I, Paterson J, Juurlink D . Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011; 171(7):686-91. DOI: 10.1001/archinternmed.2011.117. View

16.

Binswanger I, Koester S, Mueller S, Gardner E, Goddard K, Glanz J . Overdose Education and Naloxone for Patients Prescribed Opioids in Primary Care: A Qualitative Study of Primary Care Staff. J Gen Intern Med. 2015; 30(12):1837-44. PMC: 4636555. DOI: 10.1007/s11606-015-3394-3. View

17.

Gomes T, Khuu W, Craiovan D, Martins D, Hunt J, Lee K . Comparing the contribution of prescribed opioids to opioid-related hospitalizations across Canada: A multi-jurisdictional cross-sectional study. Drug Alcohol Depend. 2018; 191:86-90. DOI: 10.1016/j.drugalcdep.2018.06.028. View

18.

Gomes T, Greaves S, Tadrous M, Mamdani M, Paterson J, Juurlink D . Measuring the Burden of Opioid-related Mortality in Ontario, Canada. J Addict Med. 2018; 12(5):418-419. PMC: 6200374. DOI: 10.1097/ADM.0000000000000412. View